Sagimet Biosciences Inc. (SGMT) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$10.25

From 52W high−11.15%

Volume559913.00

Market cap$703.77M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$10.25

From 52W high

−11.15%

Volume

559913.00

Market cap

$703.77M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−9.4x

P/E (TTM)

—

RSI (14)

50.7

MomentumView details →

1D Return

−0.25%

YTD Return

+63.94%

SummaryUpdated Jun 1, 2026

Sagimet Biosciences Inc. (NASDAQ:SGMT) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in San Mateo, California. Originally incorporated as 3-V Biosciences, Inc., the company changed its name to Sagimet Biosciences in August 2019 and went public in July 2023. The company specializes in developing innovative therapeutics that target fatty acid synthase (FASN) inhibitors to treat diseases caused by dysfunctional lipid metabolism pathways, representing a novel approach in addressing metabolic disorders and certain cancers.

Ask drillr about Sagimet Biosciences Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−9.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.7x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−18.38%

ROA (TTM)

−17.87%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+30.05%

FCF YoY

+23.80%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−8.97%

EBITDA YoY

+19.40%

MomentumView details →

1D Return

−0.25%

YTD Return

+63.94%

1Y Return

+24.90%

RSI (14)

50.7

vs 50D SMA

−2.02%

vs 200D SMA

+28.54%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

45.02x

Quick Ratio

45.02x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.26

EPS Surprise

−3.59%

Beats (12Q)

10/12

Next Q EPS Est

−$0.28

Avg Surprise (4Q)

11.79%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−47.08M

Op. CF (TTM)

−41.32M

Next earningsNov 12, 2026 →

Latest newsMore news →

Sagimet Biosciences Inc. dosed the first patient in AURORA, its U.S. Phase 3 trial of denifanstat for moderate to severe acne.13d ago

Sagimet announced that positive 52-week results and mechanistic data from Ascletis' Phase 3 ASC40-304 open-label extension trial of denifanstat in acne will be presented at the 2026 Fall Clinical Dermatology Conference.26d ago

Similar companies

Attovia Therapeutics, Inc.ATTO Solid Biosciences Inc.SLDB Achieve Life Sciences, Inc.ACHV Wave Life Sciences Ltd.WVE Obsidian Therapeutics Inc.OBX Candel Therapeutics, Inc.CADL Find similar companies →

Latest newsMore news →

Sagimet Biosciences Inc. dosed the first patient in AURORA, its U.S. Phase 3 trial of denifanstat for moderate to severe acne.13d ago Sagimet announced that positive 52-week results and mechanistic data from Ascletis' Phase 3 ASC40-304 open-label extension trial of denifanstat in acne will be presented at the 2026 Fall Clinical Dermatology Conference.26d ago Sagimet Biosciences announced positive 52-week results from license partner Ascletis BioScience's Phase 3 ASC40-304 open-label extension trial of denifanstat in moderate to severe acne vulgaris, presented at EADV 2026.35d ago